Chronic-induced urticaria; classification, actual aspects of diagnosis and therapy

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Chronic-induced urticaria is a group of diseases characterized by the occurrence of itchy wheals and/or angioedema in response to specific triggers, such as mechanical irritation, exposure to high and low temperatures, vibration, and ultraviolet radiation of various spectra, appearing for ≥6 weeks. This group of diseases is characterized by a long duration, a significant effect on the patient’s quality of life, and the risk of severe life-threatening reactions.

The diagnosis of induced urticaria and patient-safe reproduction of symptoms by exposure to a trigger (temperature, mechanical, etc.). Currently, no medical devices have been registered in the Russian Federation for the threshold diagnosis of most physical forms of urticaria. Consequently, diagnosing and dynamic monitoring the state of these patients and their response to treatment are challenging. The question of therapy for chronic-induced urticaria also remains open due to the insufficient effectiveness of the recommended and available treatment methods. This article provides a review of current literature data.

This article provides a review of current literature data.

Full Text

Restricted Access

About the authors

Sofia A. Serdotetskova

City Clinical Hospital No. 52; Research Institute of Health Organization and Medical Management of the Department of Health of the City of Moscow

Email: darklynx813@gmail.com
ORCID iD: 0000-0001-8472-1152
SPIN-code: 6644-6715
Россия, Moscow; Moscow

Inna V. Danilychevа

National Research Center ― Institute of Immunology Federal Medical-Biological Agency of Russia

Email: ivdanilycheva@mail.ru
ORCID iD: 0000-0002-8279-2173
SPIN-code: 4547-3948

MD, Cand. Sci. (Med.)

Россия, Moscow

Daria S. Fomina

City Clinical Hospital No. 52; The First Sechenov Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: daria_fomina@mail.ru
ORCID iD: 0000-0002-5083-6637
SPIN-code: 3023-4538

MD, Cand. Sci. (Med.), Assistant Professor

Россия, Moscow; Moscow

Natalya P. Maltseva

City Clinical Hospital No. 52

Email: filippova-nataly@mail.ru
ORCID iD: 0000-0002-4022-3570
SPIN-code: 2588-5718
Россия, Moscow

Elena V. Kovalkova

City Clinical Hospital No. 52

Email: ev-kovalkova@ya.ru
ORCID iD: 0000-0002-1212-3767
SPIN-code: 3078-0976
Россия, Moscow

Marina S. Lebedkina

City Clinical Hospital No. 52

Email: marina.ivanova0808@yandex.ru
ORCID iD: 0000-0002-9545-4720
SPIN-code: 1857-8154
Россия, Moscow

Alexander V. Karaulov

The First Sechenov Moscow State Medical University (Sechenov University)

Email: drkaraulov@mail.ru
ORCID iD: 0000-0002-1930-5424
SPIN-code: 4122-5565

MD, Dr. Sci. (Med.), Professor

Россия, Moscow

Leyla S. Namazova-Baranova

The Russian National Research Medical University named after N.I. Pirogov; Petrovsky National Research Centre of Surgery, Research Institute of Pediatrics and Child Health Protection of the Scientific and Clinical Center No. 2

Email: Leyla.s.namazova@gmail.com
ORCID iD: 0000-0002-2209-7531
SPIN-code: 3363-6170

MD, Dr. Sci. (Med.), Professor

Россия, Moscow; Moscow

Elena A. Vishneva

The Russian National Research Medical University named after N.I. Pirogov; Petrovsky National Research Centre of Surgery, Research Institute of Pediatrics and Child Health Protection of the Scientific and Clinical Center No. 2

Email: vishneva.e@yandex.ru
ORCID iD: 0000-0001-7398-0562
SPIN-code: 1109-2810

MD, Dr. Sci. (Med.), Professor

Россия, Moscow; Moscow

Julia G. Levina

The Russian National Research Medical University named after N.I. Pirogov; Petrovsky National Research Centre of Surgery, Research Institute of Pediatrics and Child Health Protection of the Scientific and Clinical Center No. 2

Email: julia.levina@mail.ru
ORCID iD: 0000-0002-2460-7718
SPIN-code: 4626-2800

MD, Cand. Sci. (Med.)

Россия, Moscow; Moscow

Vera G. Kalugina

The Russian National Research Medical University named after N.I. Pirogov; Petrovsky National Research Centre of Surgery, Research Institute of Pediatrics and Child Health Protection of the Scientific and Clinical Center No. 2

Email: v-starikova@mail.ru
ORCID iD: 0000-0002-3781-8661
SPIN-code: 7168-3817

MD, Cand. Sci. (Med.)

Россия, Moscow; Moscow

References

  1. Maurer M, Fluhr JW, Khan DA. How to approach chronic inducible urticaria. J Allergy Clin Immunol Pract. 2018;6(4):1119–1130. doi: 10.1016/j.jaip.2018.03.007
  2. Abajian M, Schoepke N, Altrichter S, et al. Physical urticarias and cholinergic urticaria. Immunol Allergy Clin North Am. 2014;34(1): 73–88. doi: 10.1016/j.iac.2013.09.010
  3. Curto-Barredo L, Archilla LR, Vives GR, et al. Clinical features of chronic spontaneous urticaria that predict disease prognosis and refractoriness to standard treatment. Acta Derm Venereol. 2018;98(7):641–647. doi: 10.2340/00015555-2941
  4. Maurer M, Giménez-Arnau A, Ensina LF, et al. Chronic urticaria treatment patterns and changes in quality of life: AWARE Study 2-year results. World Allergy Organ J. 2020;13(9):100460. doi: 10.1016/j.waojou.2020.100460
  5. Maurer M, Hawro T, Krause K, et al. Diagnosis and treatment of chronic inducible urticaria. Allergy. 2019;74(12):2550–2553. doi: 10.1111/all.13878
  6. Schoepke N, Młynek A, Weller K, et al. Symptomatic dermographism: An inadequately described disease. J Eur Acad Dermatol Venereol. 2015;29(4):708–712. doi: 10.1111/jdv.12661
  7. Sánchez J, Amaya E, Acevedo A, et al. Prevalence of inducible urticaria in patients with chronic spontaneous urticaria: Associated risk factors. J Eur Acad Dermatol Venereol. 2017;5(2):464–470. doi: 10.1016/j.jaip.2016.09.029
  8. Abajian M, Młynek A, Maurer M. Physical urticaria. Curr Allergy Asthma Rep. 2012;12(4):281–287. doi: 10.1007/s11882-012-0269-0
  9. Fleischer M, Grabbe J. [Physical urticaria. (In German)]. Hautarzt. 2004;55(4):344–349. doi: 10.1007/s00105-004-0691-x
  10. Zuberbier T, Maurer M. Urticaria: current opinions about etiology, diagnosis and therapy. Acta Derm Venereol. 2007;87(3):196–205. doi: 10.2340/00015555-0240
  11. Urticaria (KR). Clinical recommendations, revision 2022. Russian Society of Allergologists and Clinical Immunologists, Russian Society of Dermatovenerologists and Cosmetologists, Union of Pediatricians of Russia; 2019. 57 p. (In Russ).
  12. Van der Valk PG, Moret G, Kiemeney LA. The natural history of chronic urticaria and angioedema in patients visiting a tertiary referral centre. Br J Dermatol. 2002;146(1):110–113. doi: 10.1046/j.1365-2133.2002.04582.x
  13. Magerl M, Schmolke J, Metz M, et al. Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg. Clin Exp Dermatol. 2009;34(5):e137–e140. doi: 10.1111/j.1365-2230.2008.03097.x
  14. Sharpe GR, Shuster S. The effect of cetirizine on symptoms and wealing in dermographic urticaria. Br J Dermatol. 1993;129(5): 580–583. doi: 10.1111/j.1365-2133.1993.tb00488.x
  15. Zuberbier T, Aberer W, Asero R, et al. The EAACI/GA(2)LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393–1414. doi: 10.1111/all.13397
  16. Krause K, Ardelean E, Kessler B, et al. Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy. Allergy. 2010;65(11):1494–1495. doi: 10.1111/j.1398-9995.2010.02409.x
  17. Metz M, Altrichter S, Ardelean E, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol. 2011;154(2):177–180. doi: 10.1159/000320233
  18. Maurer M, Metz M, Brehler R, et al. Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence. J Allergy Clin Immunol. 2018;141(2):638–649. doi: 10.1016/j.jaci.2017.06.032
  19. Maurer M, Schütz A, Weller K, et al. Omalizumab is effective in symptomatic dermographism-results of a randomized placebo-controlled trial. J Allergy Clin Immunol. 2017;140(3):870–873.e5. doi: 10.1016/j.jaci.2017.01.042
  20. Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis. J Dermatol Sci. 2014;73(1):57–62. doi: 10.1016/j.jdermsci.2013.08.011
  21. Metz M, Ohanyan T, Church MK, Maurer M. Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria. JAMA Dermatol. 2014;150(3):288–290. doi: 10.1001/jamadermatol.2013.8705
  22. Magerl M, Altrichter S, Borzova E, et al. The definition, diagnostic testing, and management of chronic inducible urticarias--The EAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016;71(6):780–802. doi: 10.1111/all.12884
  23. Grattan CE. The urticaria spectrum: Recognition of clinical patterns can help management. Clin Exp Dermatol. 2004;29(3): 217–221. doi: 10.1111/j.1365-2230.2004.01494.x
  24. Neittaanmäki H. Cold urticaria. Clinical findings in 220 patients. J Am Acad Dermatol. 1985;13(4):636–644. doi: 10.1016/s0190-9622(85)70208-3
  25. Siebenhaar F, Staubach P, Metz M, et al. Peltier effect-based temperature challenge: An improved method for diagnosing cold urticaria. J Allergy Clin Immunol. 2004;114(5):1224–1225. doi: 10.1016/j.jaci.2004.07.018
  26. Wanderer AA. Cold urticaria syndromes: historical background, diagnostic classification, clinical and laboratory characteristics, pathogenesis, and management. J Allergy Clin Immunol. 1990; 85(6):965–981. doi: 10.1016/0091-6749(90)90037-5
  27. Siebenhaar F, Weller K, Mlynek A, et al. Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clin Exp Dermatol. 2007;32(3):241–245. doi: 10.1111/j.1365-2230.2007.02376.x
  28. Möller A, Henz BM. Cold urticaria. In: Henz BM, Zuberbier T, Grabbe J, Monroe E, editors. Urticaria. Springer; 1998. Р. 69–78.
  29. Wanderer AA, Grandel KE, Wasserman SI, Farr RS. Clinical characteristics of cold-induced systemic reactions in acquired cold urticaria syndromes: Recommendations for prevention of this complication and a proposal for a diagnostic classification of cold urticaria. J Allergy Clin Immunol. 1986;78(3 Pt 1):417–423. doi: 10.1016/0091-6749(86)90027-8
  30. Doeglas HM, Rijnten WJ, Schröder FP, Schirm J. Cold urticaria and virus infections: A clinical and serological study in 39 patients. Br J Dermatol. 1986;114(3):311–318. doi: 10.1111/j.1365-2133.1986.tb02822.x
  31. Jain SV, Mullins RJ. Cold urticaria: A 20-year follow-up study. J Eur Acad Dermatol Venereol. 2016;30(12):2066–2071. doi: 10.1111/jdv.13841
  32. Deza G, Brasileiro A, Bertolín-Colilla M, et al. Acquired cold urticaria: Clinical features, particular phenotypes, and disease course in a tertiary care center cohort. J Am Acad Dermatol. 2016;75(5): 918–924.e2. doi: 10.1016/j.jaad.2016.06.017
  33. Tannert KL, Skov SP, Jensen BL, et al. Cold urticaria patients exhibit normal skin levels of functional mast cells and histamine after tolerance induction. Dermatology (Basel, Switzerland). 2012;224(2):101–105. doi: 10.1159/000336572
  34. Stepaniuk P, Vostretsova K, Kanani A. Review of cold-induced urticaria characteristics, diagnosis and management in a Western Canadian allergy practice. Allergy Asthma Clin Immunol. 2018;(14):85. doi: 10.1186/s13223-018-0310-5
  35. Mathelier-Fusade P, Aïssaoui M, Bakhos D, et al. Clinical predictive factors of severity in cold urticaria. Arch Dermatol. 1998;134(1):106–107. doi: 10.1001/archderm.134.1.106
  36. Młynek A, Magerl M, Siebenhaar F, et al. Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria. Br J Dermatol. 2010;162(1):198–200. doi: 10.1111/j.1365-2133.2009.09441.x
  37. Siebenhaar F, Degener F, Zuberbier T, et al. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standard-dose treatment in patients with acquired cold urticaria: A randomized, placebo-controlled, crossover study. J Allergy Clin Immunol. 2009;123(3):672–679. doi: 10.1016/j.jaci.2008.12.008
  38. Claudy A. Cold urticaria. J Investig Dermatol Symp Proc. 2001;6(2):141–142. doi: 10.1046/j.0022-202x.2001.00028.x
  39. Magerl M, Pisarevskaja D, Staubach P, et al. Critical temperature threshold measurement for cold urticaria: A randomized controlled trial of H(1)-antihistamine dose escalation. Br J Dermatol. 2012; 166(5):1095–1099. doi: 10.1111/j.1365-2133.2012.10822.x
  40. Alangari AA, Twarog FJ, Shih MC, Schneider LC. Clinical features and anaphylaxis in children with cold urticaria. Pediatrics. 2004;113(4):e313–e317. doi: 10.1542/peds.113.4.e313
  41. Kulthanan K, Hunnangkul S, Tuchinda P, et al. Treatments of cold urticaria: A systematic review. J Allergy Clin Immunol. 2019;143(4):1311–1331. doi: 10.1016/j.jaci.2019.02.005
  42. Dressler C, Werner RN, Eisert L, et al. Chronic inducible urticaria: A systematic review of treatment options. J Allergy Clin Immunol. 2018;141(5):1726–1734. doi: 10.1016/j.jaci.2018.01.031
  43. Zuberbier T. The personalized treatment for urticaria. In: Bieber T, Nestle F, editors. Personalized treatment options in dermatology. Berlin, Heidelberg: Springer; 2015. Р. 111–120.
  44. Maltseva N, Borzova E, Fomina D, et al.; COLD-CE Steering Committee. Cold urticaria--What we know and what we do not know. Allergy. 2021;76(4):1077–1094. doi: 10.1111/all.14674
  45. Metz M, Schütz A, Weller K, et al. Omalizumab is effective in cold urticaria-results of a randomized placebo-controlled trial. J Allergy Clin Immunol. 2017;140(3):864–867.e5. doi: 10.1016/j.jaci.2017.01.043
  46. Marsland AM, Beck MH. Cold urticaria responding to systemic ciclosporin. Br J Dermatol. 2003;149(1):214–215. doi: 10.1046/j.1365-2133.2003.05414.x
  47. Czarnetzki BM. Ketotifen in cholinergic urticaria. J Allergy Clin Immunol. 1990;86(1):138–139. doi: 10.1016/s0091-6749(05)80136-8
  48. Illig L. [On the pathogenesis of cholinergic urticaria. I. Clinical observations and histological studies. (In German)]. Arch Klin Exp Dermatol. 1967;229(3):231–247.
  49. Illig L, Heinicke A. [On the pathogenesis of cholinergic urticaria. II. Studies on the relationships of cholinergic urticaria to sweat secretions with the help of various cholinomimetics. (In German)]. Arch Klin Exp Dermatol. 1967;229(3):285–299.
  50. Illig L, Heinicke A. [On the pathogenesis of cholinergic urticaria. III. The influence of sweat secretion inhibition on cholinergic urticaria. (In German)]. Arch Klin Exp Dermatol. 1967;229(3):345–359.
  51. Illig L, Heinicke A. [On the pathogenesis of cholinergic urticaria. IV. On the problem of a true antigen-antibody reaction. (In German)]. Arch Klin Exp Dermatol. 1967;229(3):360–371.
  52. Illig L, Heinicke A. [Pathogenesis of cholinergic urticaria. V. The pharmacologic reactivity of the Prausnitz-Kustner reaction and the origin of the antigen. (In German)]. Arch Klin Exp Dermatol. 1967;230(1):34–47.
  53. Altrichter S, Koch K, Church MK, Maurer M. Atopic predisposition in cholinergic urticaria patients and its implications. J Eur Acad Dermatol Venereol. 2016;30(12):2060–2065. doi: 10.1111/jdv.13765
  54. Asady A, Ruft J, Ellrich A, et al. Cholinergic urticaria patients of different age groups have distinct features. Clin Exp Allergy. 2017;47(12):1609–1614. doi: 10.1111/cea.13023
  55. Horikawa T, Fukunaga A, Nishigori C. New concepts of hive formation in cholinergic urticaria. Curr Allergy Asthma Rep. 2009; 9(4):273–279. doi: 10.1007/s11882-009-0038-x
  56. Bito T, Sawada Y, Tokura Y. Pathogenesis of cholinergic urticaria in relation to sweating. Allergol Int. 2012;61(4):539–544. doi: 10.2332/allergolint.12-RAI-0485
  57. Washio K, Fukunaga A, Onodera M, et al. Clinical characteristics in cholinergic urticaria with palpebral angioedema: Report of 15 cases. J Dermatol Sci. 2017;85(2):135–137. doi: 10.1016/j.jdermsci.2016.11.001
  58. Fukunaga A, Bito T, Tsuru K, et al. Responsiveness to autologous sweat and serum in cholinergic urticaria classifies its clinical subtypes. J Allergy Clin Immunol. 2005;116(2):397–402. doi: 10.1016/j.jaci.2005.05.024
  59. Sawada Y, Nakamura M, Bito T, et al. Decreased expression of acetylcholine esterase in cholinergic urticaria with hypohidrosis or anhidrosis. J Invest Dermatol. 2014;134(1):276–279. doi: 10.1038/jid.2013.244
  60. Fukunaga A, Hatakeyama M, Tsujimoto M, et al. Steroid treatment can improve the impaired quality of life of patients with acquired idiopathic generalized anhidrosis. Br J Dermatol. 2015;172(2): 537–538. doi: 10.1111/bjd.13285
  61. Kim JE, Jung KH, Cho HH, et al. The significance of hypersensitivity to autologous sweat and serum in cholinergic urticaria: cholinergic urticaria may have different subtypes. Int J Dermatol. 2015;54(7): 771–777. doi: 10.1111/ijd.12549
  62. Shelley WB, Rawnsley HM. Aquagenic urticaria. Contact sensitivity reaction to water. JAMA. 1964;(189):895–898.
  63. Shelley WB, Shelley ED. Follicular dermographism. Cutis. 1983;32(3):244–260.
  64. Nakamizo S, Egawa G, Miyachi Y, Kabashima K. Cholinergic urticaria: Pathogenesis-based categorization and its treatment options. J Eur Acad Dermatol Venereol. 2012;26(1):114–116. doi: 10.1111/j.1468-3083.2011.04017.x
  65. Munetsugu T, Fujimoto T, Oshima Y, et al. Revised guideline for the diagnosis and treatment of acquired idiopathic generalized anhidrosis in Japan. J Dermatol. 2017;44(4):394–400. doi: 10.1111/1346-8138.13649
  66. Altrichter S, Salow J, Ardelean E, et al. Development of a standardized pulse-controlled ergometry test for diagnosing and investigating cholinergic urticaria. J Dermatol Sci. 2014;75(2):88–93. doi: 10.1016/j.jdermsci.2014.04.007
  67. Zuberbier T, Aberer W, Burtin B, et al. Efficacy of cetirizine in cholinergic urticaria. Acta Derm Venereol. 1995;75(2):147–149. doi: 10.2340/0001555575147149
  68. Zuberbier T, Münzberger C, Haustein U, et al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology (Basel, Switzerland). 1996;193(4):324–327. doi: 10.1159/000246281
  69. Koch K, Weller K, Werner A, et al. Antihistamine updosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria. J Allergy Clin Immunol. 2016;138(5):1483–1485.e9. doi: 10.1016/j.jaci.2016.05.026
  70. Ghazanfar MN, Sand C, Thomsen SF. Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: Evaluation of 154 patients. Br J Dermatol. 2016;175(2):404–406. doi: 10.1111/bjd.14540
  71. Metz M, Bergmann P, Zuberbier T, Maurer M. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy. 2008;63(2):247–249. doi: 10.1111/j.1398-9995.2007.01591.x
  72. Otto HF, Calabria CW. A case of severe refractory chronic urticaria: A novel method for evaluation and treatment. Allergy Asthma Proc. 2009;30(3):333–337. doi: 10.2500/aap.2009.30.3237
  73. Sabroe RA. Failure of omalizumab in cholinergic urticaria. Clin Exp Dermatol. 2010;35(4):e127–e129. doi: 10.1111/j.1365-2230.2009.03748.x
  74. Kutlu A, Tanoglu A, Ozturk S. Healing effects of omalizumab in a patient with cholinergic urticaria associated severe dyspeptic complaints. Chin Med J (Engl). 2015;128(11):1559–1560. doi: 10.4103/0366-6999.157703
  75. Ujiie H, Shimizu T, Natsuga K, et al. Severe cholinergic urticaria successfully treated with scopolamine butylbromide in addition to antihistamines. Clin Exp Dermatol. 2006;31(4):588–589. doi: 10.1111/j.1365-2230.2006.02117.x
  76. Altrichter S, Wosny K, Maurer M. Successful treatment of cholinergic urticaria with methantheliniumbromide. J Dermatol. 2015;42(4):422–424. doi: 10.1111/1346-8138.12765
  77. Feinberg JH, Toner CB. Successful treatment of disabling cholinergic urticaria. Military Med. 2008;173(2):217–220. doi: 10.7205/milmed.173.2.217
  78. Sheraz A, Halpern S. Cholinergic urticaria responding to botulinum toxin injection for axillary hyperhidrosis. Br J Dermatol. 2013;168(6):1369–1370. doi: 10.1111/bjd.12200
  79. Berth-Jones J, Graham-Brown RA. Cholinergic pruritus, erythema and urticaria: A disease spectrum responding to danazol. Br J Dermatol. 1989;121(2):235–237. doi: 10.1111/j.1365-2133.1989.tb01804.x
  80. La Shell MS, England RW. Severe refractory cholinergic urticaria treated with danazol. J Drugs Dermatol. 2006);5(7):664–667.
  81. Wong E, Eftekhari N, Greaves MW, Ward AM. Beneficial effects of danazol on symptoms and laboratory changes in cholinergic urticaria. Br J Dermatol. 1987;116(4):553–556. doi: 10.1111/j.1365-2133.1987.tb05877.x
  82. Lawlor F, Black AK. Delayed pressure urticaria. Immunol Allergy Clin North Am. 2004;24(2):247-vii. doi: 10.1016/j.iac.2004.01.006
  83. Hermes B, Prochazka AK, Haas N, et al. Upregulation of TNF-alpha and IL-3 expression in lesional and uninvolved skin in different types of urticaria. J Allergy Clin Immunol. 1999;103 (2 Pt 1):307–314. doi: 10.1016/s0091-6749(99)70506-3
  84. Ryan TJ, Shim-Young N, Turk JL. Delayed pressure urticaria. Br J Dermatol. 1968;80(8):485–490. doi: 10.1111/j.1365-2133.1968.tb12334.x
  85. Barlow RJ, Warburton F, Watson K, et al. Diagnosis and incidence of delayed pressure urticaria in patients with chronic urticaria. J Am Acad Dermatol. 1993;29(6):954–958. doi: 10.1016/0190-9622(93)70273-v
  86. Lawlor F, Black AK, Ward AM, et al. Delayed pressure urticaria, objective evaluation of a variable disease using a dermographometer and assessment of treatment using colchicine. Br J Dermatol. 1989;120(3):403–408. doi: 10.1111/j.1365-2133.1989.tb04167.x
  87. Magerl M, Philipp S, Manasterski M, et al. Successful treatment of delayed pressure urticaria with anti-TNF-alpha. J Allergy Clin Immunol. 2007;119(3):752–754. doi: 10.1016/j.jaci.2006.12.658
  88. Morgan M, Khan DA. Therapeutic alternatives for chronic urticaria: An evidence-based review, Part 1. Ann Allergy Asthma Immunol. 2008;100(5)403–468. doi: 10.1016/S1081-1206(10)60462-0
  89. Morgan M, Khan DA. Therapeutic alternatives for chronic urticaria: An evidence-based review. Part 2 // Ann Allergy Asthma Immunol. 2008;100(6):517–544. doi: 10.1016/S1081-1206(10)60047-6
  90. Eskeland S, Tanum L, Halvorsen JA. Delayed pressure urticaria treated with the selective serotonin reuptake inhibitor escitalopram. Clin Exp Dermatol. 2016;41(5):526–528. doi: 10.1111/ced.12851
  91. Swerlick RA, Puar N. Delayed pressure urticaria: response to treatment with sulfasalazine in a case series of seventeen patients. Dermatol Ther. 2015;28(5):318–322. doi: 10.1111/dth.12266
  92. Samarasinghe V, Marsland AM. Class action of oral coumarins in the treatment of a patient with chronic spontaneous urticaria and delayed-pressure urticaria. Clin Exp Dermatol. 2012; 37(7):741–743. doi: 10.1111/j.1365-2230.2011.04281.x
  93. Grundmann SA, Kiefer S, Luger TA, Brehler R. Delayed pressure urticaria--dapsone heading for first-line therapy? J Dtsch Dermatol Ges. 2011;9(11):908–912. doi: 10.1111/j.1610-0387.2011.07749.x
  94. Shedden C, Highet AS. Delayed pressure urticaria controlled by tranexamic acid. Clin Exp Dermatol. 2006;31(2):295–296. doi: 10.1111/j.1365-2230.2005.02014.x
  95. Kalogeromitros D, Kempuraj D, Katsarou-Katsari A, et al. Theophylline as “add-on” therapy in patients with delayed pressure urticaria: A prospective self-controlled study. Int J Immunopathol Pharmacol. 2005;18(3):595–602. doi: 10.1177/039463200501800320
  96. Dawn G, Urcelay M, Ah-Weng A, et al. Effect of high-dose intravenous immunoglobulin in delayed pressure urticaria. Br J Dermatol. 2003;149(4):836–840. doi: 10.1046/j.1365-2133.2003.05486.x
  97. Nettis E, Pannofino A, Cavallo E, et al. Efficacy of montelukast, in combination with loratadine, in the treatment of delayed pressure urticaria. J Allergy Clin Immunol. 2003;112(1):212–213. doi: 10.1067/mai.2003.1559
  98. Bindslev-Jensen C, Skov PS. Efficacy of omalizumab in delayed pressure urticaria: A case report. Allergy. 2010;65(1):138–139. doi: 10.1111/j.1398-9995.2009.02188.x
  99. Quintero OP, Arrondo AP, Veleiro B. Rapid response to omalizumab in 3 cases of delayed pressure urticaria. J Allergy Clin Immunol Pract. 2017;5(1):179–180. doi: 10.1016/j.jaip.2016.07.016
  100. Netchiporouk E, Nguyen CH, Thuraisingham T, et al. Management of pediatric chronic spontaneous and physical urticaria patients with omalizumab: Case series. Pediatr Allergy Immunol. 2015;26(6):585–588. doi: 10.1111/pai.12407
  101. Kasperska-Zajac A, Jarząb J, Żerdzińska A, et al. Effective treatment of different phenotypes of chronic urticaria with omalizumab: Case reports and review of literature. Int J Immunopathol Pharmacol. 2016;29(2):320–328. doi: 10.1177/0394632015623795
  102. Milanesi N, Gola M, Francalanci S. Evaluation of nine patients with solar urticaria during summer. G Ital Dermatol Venereol. 2020; 155(6):800–802. doi: 10.23736/S0392-0488.19.06176-5
  103. Snast I, Lapidoth M, Uvaidov V, et al. Real-life experience in the treatment of solar urticaria: Retrospective cohort study. Clin Exp Dermatol. 2019;44(5):e164–e170. doi: 10.1111/ced.13960
  104. Photiou L, Foley P, Ross G. Solar urticaria--An Australian case series of 83 patients. Australas J Dermatol. 2019;60(2):110–117. doi: 10.1111/ajd.12975
  105. Lyons AB, Peacock A, Zubair R, et al. Successful treatment of solar urticaria with UVA1 hardening in three patients. Photodermatol Photoimmunol Photomed. 2019;35(3):193–195. doi: 10.1111/phpp.12447
  106. Snyder M, Turrentine JE, Cruz PD. Photocontact dermatitis and its clinical mimics: an overview for the allergist. Clin Rev Allergy Immunol. 2019;56(1):32–40. doi: 10.1007/s12016-018-8696-x
  107. Fityan A, McGibbon D, Fassihi H, Sarkany RS. Paediatric solar urticaria: A case series. Br J Dermatol. 2018;178(6):1453–1454. doi: 10.1111/bjd.16325
  108. Raigosa M, Toro Y, Sánchez J. [Solar urticaria. Case report and literature review. (In Spanish)]. Rev Alerg Mex. 2017;64(3):371–375. doi: 10.29262/ram.v64i3.202
  109. Goetze S, Elsner P. Solar urticaria. J Dtsch Dermatol Ges. 2015;13(12):1250–1253. doi: 10.1111/ddg.12809
  110. Snast I, Kremer N, Lapidoth M, et al. Omalizumab for the treatment of solar urticaria: Case series and systematic review of the literature. J Allergy Clin Immunol Pract. 2018;6(4):1198–1204.e3. doi: 10.1016/j.jaip.2018.02.032
  111. Morgado-Carrasco D, Fustà-Novell X, Podlipnik S, et al. Clinical and photobiological response in eight patients with solar urticaria under treatment with omalizumab, and review of the literature. Photodermatol Photoimmunol Photomed. 2018;34(3):194–199. doi: 10.1111/phpp.12370
  112. Harris BW, Badri T, Schlessinger J. Solar Urticaria. In: StatPearls. StatPearls Publishing; 2022.
  113. Arasi S, Crisafulli G, Caminiti L, et al. Treatment with omalizumab in a 16-year-old Caucasian girl with refractory solar urticaria. Pediatr Allergy Immunol. 2015;26(6):583–585. doi: 10.1111/pai.12413
  114. Baliu-Piqué C, Aguilera Peiró P. Three cases of solar urticaria successfully treated with omalizumab. J Eur Acad Dermatol Venereol. 2016;30(4):704–706. doi: 10.1111/jdv.13001
  115. Combalia A, Fernández-Sartorio C, Aguilera P. Refractory solar urticaria successfully treated with omalizumab with normalization of phototest. Actas Dermosifiliogr. 2017;108(6):593–594. doi: 10.1016/j.ad.2016.11.015
  116. De Dios-Velázquez Á, González-de Arriba M, Beteta-Gorriti V, et al. Effectiveness of omalizumab in severe solar urticaria. Ann Allergy Asthma Immunol. 2016;116(3):260–262. doi: 10.1016/j.anai.2015.12.023
  117. Güzelbey O, Ardelean E, Magerl M, et al. Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy. 2008;63(11):1563–1565. doi: 10.1111/j.1398-9995.2008.01879.x
  118. Moncourier M, Assikar S, Matei I, et al. Visible light-induced solar urticaria is improved by omalizumab. Photodermatol Photoimmunol Photomed. 2016;32(5-6):314–316. doi: 10.1111/phpp.12271
  119. Terrani I, Bircher AJ, Hofmeier SK. Solar urticaria induced by visible light: Successful treatment with omalizumab. Clin Exp Dermatol. 2016;41(8):890–892. doi: 10.1111/ced.12951
  120. Brüning JH, Ziemer M, Pemler S, et al. Successful treatment of solar urticaria with omalizumab. J Dtsch Dermatol Ges. 2016;14(9):936–937. doi: 10.1111/ddg.13017
  121. Levi A, Tal Y, Dranitzki Z, et al. Successful omalizumab treatment of severe solar urticaria in a 6-year-old child. Pediatr Allergy Immunol. 2015;26(6):588–590. doi: 10.1111/pai.12441
  122. Müller S, Schempp CM, Jakob T. Failure of omalizumab in the treatment of solar urticaria. J Eur Acad Dermatol Venereol. 2016;30(3):524–525. doi: 10.1111/jdv.12922
  123. Darling M, Lambiase MC, Hodson DS. Localized heat induced urticaria: Report of a case. J Drugs Dermatol. 2004;3(1):75–76.
  124. Pezzolo E, Peroni A, Gisond P., Girolomoni G. Heat urticaria: A revision of published cases with an update on classification and management. Br J Dermatol. 2016;175(3):473–478. doi: 10.1111/bjd.14543
  125. Carballada F, Nuñez R, Martin-Lazaro J, et al. Omalizumab treatment in 2 cases of refractory heat urticaria. J Investig Allergol Clin Immunol. 2013;23(7):519–521.
  126. Bullerkotte U, Wieczorek D, Kapp A, Wedi B. Effective treatment of refractory severe heat urticaria with omalizumab. Allergy. 2010;65(7):931–932. doi: 10.1111/j.1398-9995.2009.02268.x
  127. Boyden SE, Desai A, Cruse G, et al. Vibratory urticaria associated with a missense variant in ADGRE2. N Engl J Med. 2016;374(7): 656–663. doi: 10.1056/NEJMoa1500611
  128. Pressler A, Grosber M, Halle M, et al. Failure of omalizumab and successful control with ketotifen in a patient with vibratory angioedema. Clin Exp Dermatol. 2013;38(2):151–153. doi: 10.1111/j.1365-2230.2012.04430.x
  129. Bhatia R, Alikhan A, Maibach HI. Contact urticaria: present scenario. Indian J Dermatol. 2009;54(3):264–268. doi: 10.4103/0019-5154.55639
  130. Mowad CM. Contact dermatitis: Practice gaps and challenges. Dermatol Clin. 2016;34(3):263–267. doi: 10.1016/j.det.2016.02.010
  131. Japundžić I, Vodanović M, Lugović-Mihić L. An analysis of skin prick tests to latex and patch tests to rubber additives and other causative factors among dental professionals and students with contact dermatoses. Int Arch Allergy Immunol. 2018;177(3):238–244. doi: 10.1159/000490181
  132. Pondeljak N, Lugović-Mihić L. Stress-induced interaction of skin immune cells, hormones, and neurotransmitters. Clin Ther. 2020;42(5):757–770. doi: 10.1016/j.clinthera.2020.03.008
  133. Kai AC, Flohr C. Aquagenic urticaria in twins. World Allergy Organ J. 2013;6(1):2. doi: 10.1186/1939-4551-6-2
  134. Park H, Kim HS, Yoo DS, et al. Aquagenic urticaria: A report of two cases. Ann Dermatol. 2011;23(Suppl 3):S371–S374. doi: 10.5021/ad.2011.23.S3.S371
  135. McGee JS, Kirkorian AY, Pappert AS, Milgraum SS. An adolescent boy with urticaria to water: Review of current treatments for aquagenic urticaria. Pediatr Dermatol. 2014;31(1):116–117. doi: 10.1111/j.1525-1470.2012.01801.x
  136. Wassef C, Laureano A, Schwartz RA. Aquagenic urticaria: A perplexing physical phenomenon. Acta Dermatovenerol Croat. 2017;25(3):234–237.
  137. Pozderac I, Lugović-Mihić L, Artuković M, et al. Chronic inducible urticaria: Classification and prominent features of physical and non-physical types. Acta Dermatovenerol Alp Pannonica Adriat. 2020;29(3):141–148.
  138. Rorie A., Gierer S. A case of aquagenic urticaria successfully treated with omalizumab. J Allergy Clin Immunol Pract. 2016;4(3): 547–548. doi: 10.1016/j.jaip.2015.12.017
  139. Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol. 2001;45(3):387–391. doi: 10.1067/mjd.2001.116217

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Frick-test. (Photo from the archive of the Moscow City Reseach and Practical Center of Allergology and Immunology Ministry of Healthcare of Moscow).

Download (89KB)
Indexing metadata
3. Fig. 2. Methodic of performing of provocation testing in patient with symptomatic dermographism. (Photo from the archive of the Moscow City Reseach and Practical Center of Allergology and Immunology Ministry of Healthcare of Moscow).

Download (88KB)
Indexing metadata
4. Fig. 3. Positive result of provocation testing in patient with symptimatic dermographism. (Photo from the archive of the Moscow City Reseach and Practical Center of Allergology and Immunology Ministry of Healthcare of Moscow).

Download (135KB)
Indexing metadata
5. Fig. 4. Positive result of the ice cube testing. (Photo from the archive of the Moscow City Reseach and Practical Center of Allergology and Immunology Ministry of Healthcare of Moscow).

Download (91KB)
Indexing metadata
6. Fig. 5. TempTest. (Photo from the archive of the Moscow City Reseach and Practical Center of Allergology and Immunology Ministry of Healthcare of Moscow).

Download (64KB)
Indexing metadata
7. Fig. 6 (a, b). Positive result of provocation testing by TempTest device in patient with cold urticarial. (Photo from the archive of the Moscow City Reseach and Practical Center of Allergology and Immunology Ministry of Healthcare of Moscow).

Download (176KB)
Indexing metadata
8. Fig. 7. Tredmill using to providing provocation testing in patient with cholinergic urticarial. (Photo from the archive of the Moscow City Reseach and Practical Center of Allergology and Immunology Ministry of Healthcare of Moscow).

Download (269KB)
Indexing metadata
9. Fig. 8 (a, b). Positive result of provocation testing in patient with cholinergic urticarial. (Photo from the archive of the Moscow City Reseach and Practical Center of Allergology and Immunology Ministry of Healthcare of Moscow).

Download (473KB)
Indexing metadata
10. Fig. 9. Positive result of provocation testing in patient with delayed pressure urticaria (test with sand bag). (Photo from the archive of the Moscow City Reseach and Practical Center of Allergology and Immunology Ministry of Healthcare of Moscow).

Download (108KB)
Indexing metadata
11. Fig. 10. Provocation testing in patient with delayed pressure urticaria by standartisated cillnders [82].

Download (161KB)
Indexing metadata
12. Fig. 11. Positive results of provocation testing in patient in patient with solar urticaria: а ― positive results of tesring with UVA specter; b ― positive results of tesring with UVB specter; с ― appearing of immediate erythema after UVA specter impact [109].

Download (209KB)
Indexing metadata

Copyright © Pharmarus Print Media, 2023



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies